PMC:3933749 / 32256-33719 JSONTXT

{"project":"NEUROSES","denotations":[{"id":"T598","span":{"begin":119,"end":123},"obj":"PATO_0000610"},{"id":"T600","span":{"begin":124,"end":129},"obj":"CHEBI_35209"},{"id":"T605","span":{"begin":191,"end":197},"obj":"PATO_0001309"},{"id":"T606","span":{"begin":891,"end":895},"obj":"PATO_0001309"},{"id":"T609","span":{"begin":891,"end":895},"obj":"PATO_0000165"},{"id":"T610","span":{"begin":343,"end":354},"obj":"CHEBI_33232"},{"id":"T611","span":{"begin":433,"end":444},"obj":"CHEBI_33232"},{"id":"T612","span":{"begin":675,"end":686},"obj":"CHEBI_33232"},{"id":"T613","span":{"begin":953,"end":964},"obj":"CHEBI_33232"},{"id":"T614","span":{"begin":576,"end":582},"obj":"PATO_0001716"},{"id":"T615","span":{"begin":1022,"end":1025},"obj":"CHEBI_52027"},{"id":"T616","span":{"begin":1183,"end":1194},"obj":"CHEBI_33232"},{"id":"T617","span":{"begin":1285,"end":1300},"obj":"CHEBI_6887"},{"id":"T618","span":{"begin":1399,"end":1414},"obj":"CHEBI_6887"}],"text":"Dermal Responses\nDermal reactions were characterized in 305 children aged 6–12 years with ADHD who were enrolled in an open-label, dose-optimization study [36]. After a 4-week dose-titration period, patients continued to wear the MTS at the optimized dose of 10, 15, 20, or 30 mg for 9 h per day on alternating hips for an additional 3 weeks. Application-site evaluations were conducted at weeks 0, 1, 2, 3, 4, 5, and 8. The current application site and the site from the previous day were scored using a 7-point dermal response score (DRS), where 0 is no irritation and 7 is strong reaction spreading beyond the test site. At the scheduled visits, evaluation of the current application site showed that 46.9 % of patients had DRS scores of ≤1. Another 49 % had DRS scores of 2, 2.0 % had DRS scores of 3, and 1.0 % (four patients) had DRS scores of 4. No DRS scores \u003e4 were reported at any time during the trial. In an assessment of the previous day’s application sites, 82 % of patients had DRS scores of ≤1. DRS scores did not tend to increase with increasing MTS doses. More than 90 % of patients reported either no discomfort or mild discomfort at the current or previous day’s application site. Three of the four patients with a DRS score of 4 were successfully switched to oral methylphenidate. The fourth individual withdrew from the study and subsequently had a mild patch test response to methylphenidate, indicating allergic contact sensitization [36]."}